OBI Pharma’s Board of Directors approves the announcement of the Company’s 2016 individual and consolidated financial statements

  1. Date of the Event: 9 Mar 2017
  2. Company Name: OBI Pharma, Inc
  3. Relationship to the Company (enter “Parent” or “Subsidiary”: Parent
  4. Reciprocal shareholding ratios: N/A
  5. Reason for the Event: The Company’s 2016 individual and consolidated financial statements were
    approved by the board of directors. Essential financial items are presented below.

    • From the 2016 Individual Financial Statement
      – Operating loss:                                         (NT$ 1,110,256,000)
      – Total comprehensive loss for the period: (NT$ 1,111,256,000)
      – Loss Per Share (in dollars):                                     (NT$ 6.51)
    • From the 2016 Consolidated Financial Statement
      – Operating loss:                                         (NT$ 1,112,470,000)
      – Total comprehensive loss for the period: (NT$ 1,111,256,000)
      – Loss Per Share (in dollars):                                     (NT$ 6.51)
  6. Countermeasures: N/A
  7. Any other matters that need to be specified: None